KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.

David M. Brown, Andrés Emanuelli, Francesco Bandello, Jose Juan Escobar-Barranco, João Figueira, Eric H. Souied, Sebastián Wolf, Vishali Gupta, Nor Fariza Ngah, Gerald Liew, Raman Tuli, Ramin Tadayoni, Dilsher S. Dhoot, Lixin Wang, Emmanuel Bouillaud, Ying Wang, Lidija Kovacic, Nicolas Guérard, Justus G. Garweg

2022Bern Open Repository and Information System (University of Bern)145 citationsOpen Access PDF

Topics & Concepts

AfliberceptMedicineDosingClinical endpointDiabetic retinopathyAdverse effectVisual acuityMacular edemaRandomized controlled trialOphthalmologySurgeryInternal medicineDiabetes mellitusChemotherapyBevacizumabEndocrinologyRetinal Diseases and TreatmentsRetinal Imaging and AnalysisOcular Diseases and Behçet’s Syndrome